Frontline therapy of multiple myeloma

Frontline therapy of multiple myeloma

In the past decade, one of the major advances in the management of patients with symptomatic newly diagnosed multiple myeloma has been the introduction of novel agents, thalidomide, bortezomib, and lenalidomide, as part of frontline treatment in both transplant and nontransplant candidates. These dr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2015-05, Vol.125 (20), p.3076-3084
Hauptverfasser: Moreau, Philippe, Attal, Michel, Facon, Thierry
Format: Artikel
Sprache:eng
Schlagworte:
Age Factors
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Hematopoietic Stem Cell Transplantation
Humans
Multiple Myeloma - therapy
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3084
container_issue 20
container_start_page 3076
container_title Blood
container_volume 125
creator Moreau, Philippe
Attal, Michel
Facon, Thierry
description In the past decade, one of the major advances in the management of patients with symptomatic newly diagnosed multiple myeloma has been the introduction of novel agents, thalidomide, bortezomib, and lenalidomide, as part of frontline treatment in both transplant and nontransplant candidates. These drugs have markedly improved the rate of complete remission, and time to progression, progression-free survival, and overall survival have significantly increased. This article focuses on more recent frontline therapeutic approaches both in older patients, not eligible for high-dose therapy and autologous stem cell transplantation (ASCT), and in younger patients eligible for early ASCT.
doi_str_mv 10.1182/blood-2014-09-568915
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1696683844</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120316840</els_id><sourcerecordid>1696683844</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-d1539f9509751dea85f716a28ed010da770993ba7b061291087b5deaf025ab6a3</originalsourceid><addsrcrecordid>eNp9kMFKxDAQhoMouq6-gUgvgpfoJE2a5iLI4qqw4EXPIW2nGGmbmrTCvr1du3r0NJfvn3_mI-SCwQ1jOb8tGu8ryoEJCprKLNdMHpAFkzynABwOyQIAMiq0YifkNMYPmNiUy2NywmWe5qmQC3K1Dr4bGtdhMrxjsP028XXSjs3g-gaTdouNb-0ZOaptE_F8P5fkbf3wunqim5fH59X9hpZCiYFWTKa61hK0kqxCm8tasczyHCtgUFmlQOu0sKqAjHHNIFeFnLgauLRFZtMluZ739sF_jhgH07pYYtPYDv0YDct0lk2nCzGhYkbL4GMMWJs-uNaGrWFgdoLMjyCzE2RAm1nQFLvcN4xFi9Vf6NfIBNzNAE5_fjkMJpYOuxIrF7AcTOXd_w3fMi11qQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1696683844</pqid></control><display><type>article</type><title>Frontline therapy of multiple myeloma</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Moreau, Philippe ; Attal, Michel ; Facon, Thierry</creator><creatorcontrib>Moreau, Philippe ; Attal, Michel ; Facon, Thierry</creatorcontrib><description>In the past decade, one of the major advances in the management of patients with symptomatic newly diagnosed multiple myeloma has been the introduction of novel agents, thalidomide, bortezomib, and lenalidomide, as part of frontline treatment in both transplant and nontransplant candidates. These drugs have markedly improved the rate of complete remission, and time to progression, progression-free survival, and overall survival have significantly increased. This article focuses on more recent frontline therapeutic approaches both in older patients, not eligible for high-dose therapy and autologous stem cell transplantation (ASCT), and in younger patients eligible for early ASCT.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2014-09-568915</identifier><identifier>PMID: 25838345</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Age Factors ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Hematopoietic Stem Cell Transplantation ; Humans ; Multiple Myeloma - therapy ; Treatment Outcome</subject><ispartof>Blood, 2015-05, Vol.125 (20), p.3076-3084</ispartof><rights>2015 American Society of Hematology</rights><rights>2015 by The American Society of Hematology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-d1539f9509751dea85f716a28ed010da770993ba7b061291087b5deaf025ab6a3</citedby><cites>FETCH-LOGICAL-c474t-d1539f9509751dea85f716a28ed010da770993ba7b061291087b5deaf025ab6a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25838345$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moreau, Philippe</creatorcontrib><creatorcontrib>Attal, Michel</creatorcontrib><creatorcontrib>Facon, Thierry</creatorcontrib><title>Frontline therapy of multiple myeloma</title><title>Blood</title><addtitle>Blood</addtitle><description>In the past decade, one of the major advances in the management of patients with symptomatic newly diagnosed multiple myeloma has been the introduction of novel agents, thalidomide, bortezomib, and lenalidomide, as part of frontline treatment in both transplant and nontransplant candidates. These drugs have markedly improved the rate of complete remission, and time to progression, progression-free survival, and overall survival have significantly increased. This article focuses on more recent frontline therapeutic approaches both in older patients, not eligible for high-dose therapy and autologous stem cell transplantation (ASCT), and in younger patients eligible for early ASCT.</description><subject>Age Factors</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Multiple Myeloma - therapy</subject><subject>Treatment Outcome</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMFKxDAQhoMouq6-gUgvgpfoJE2a5iLI4qqw4EXPIW2nGGmbmrTCvr1du3r0NJfvn3_mI-SCwQ1jOb8tGu8ryoEJCprKLNdMHpAFkzynABwOyQIAMiq0YifkNMYPmNiUy2NywmWe5qmQC3K1Dr4bGtdhMrxjsP028XXSjs3g-gaTdouNb-0ZOaptE_F8P5fkbf3wunqim5fH59X9hpZCiYFWTKa61hK0kqxCm8tasczyHCtgUFmlQOu0sKqAjHHNIFeFnLgauLRFZtMluZ739sF_jhgH07pYYtPYDv0YDct0lk2nCzGhYkbL4GMMWJs-uNaGrWFgdoLMjyCzE2RAm1nQFLvcN4xFi9Vf6NfIBNzNAE5_fjkMJpYOuxIrF7AcTOXd_w3fMi11qQ</recordid><startdate>20150514</startdate><enddate>20150514</enddate><creator>Moreau, Philippe</creator><creator>Attal, Michel</creator><creator>Facon, Thierry</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150514</creationdate><title>Frontline therapy of multiple myeloma</title><author>Moreau, Philippe ; Attal, Michel ; Facon, Thierry</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-d1539f9509751dea85f716a28ed010da770993ba7b061291087b5deaf025ab6a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Age Factors</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Multiple Myeloma - therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moreau, Philippe</creatorcontrib><creatorcontrib>Attal, Michel</creatorcontrib><creatorcontrib>Facon, Thierry</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moreau, Philippe</au><au>Attal, Michel</au><au>Facon, Thierry</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Frontline therapy of multiple myeloma</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2015-05-14</date><risdate>2015</risdate><volume>125</volume><issue>20</issue><spage>3076</spage><epage>3084</epage><pages>3076-3084</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>In the past decade, one of the major advances in the management of patients with symptomatic newly diagnosed multiple myeloma has been the introduction of novel agents, thalidomide, bortezomib, and lenalidomide, as part of frontline treatment in both transplant and nontransplant candidates. These drugs have markedly improved the rate of complete remission, and time to progression, progression-free survival, and overall survival have significantly increased. This article focuses on more recent frontline therapeutic approaches both in older patients, not eligible for high-dose therapy and autologous stem cell transplantation (ASCT), and in younger patients eligible for early ASCT.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25838345</pmid><doi>10.1182/blood-2014-09-568915</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2015-05, Vol.125 (20), p.3076-3084
issn 0006-4971
1528-0020
language eng
recordid cdi_proquest_miscellaneous_1696683844
source MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Age Factors
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Hematopoietic Stem Cell Transplantation
Humans
Multiple Myeloma - therapy
Treatment Outcome
title Frontline therapy of multiple myeloma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T20%3A27%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Frontline%20therapy%20of%20multiple%20myeloma&rft.jtitle=Blood&rft.au=Moreau,%20Philippe&rft.date=2015-05-14&rft.volume=125&rft.issue=20&rft.spage=3076&rft.epage=3084&rft.pages=3076-3084&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2014-09-568915&rft_dat=%3Cproquest_cross%3E1696683844%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1696683844&rft_id=info:pmid/25838345&rft_els_id=S0006497120316840&rfr_iscdi=true